Ashland Inc.
NYSE•ASH
CEO: Mr. Guillermo Novo
Sector: Basic Materials
Industry: Chemicals - Specialty
Listing Date: 1980-03-17
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; and nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives. Its Personal Care segment provides a range of natural, nature-derived, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022. Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.
Contact Information
Market Cap
$2.41B
P/E (TTM)
-3.5
28.2
Dividend Yield
3.2%
52W High
$65.65
52W Low
$45.21
52W Range
Rank42Top 47.5%
3.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$386.00M-4.69%
4-Quarter Trend
EPS
-$0.26-92.57%
4-Quarter Trend
FCF
$111.00M-276.19%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Net Loss Significantly Narrows Net loss reduced to $(12)M for the quarter, a $153M improvement versus prior year period results.
Operating Cash Flow Strong Cash provided by operating activities from continuing operations reached $125M, up from $(30)M outflow last year.
Adjusted EBITDA Slight Dip Adjusted EBITDA was $58M, slightly down $3M from $61M, driven by portfolio optimization impacts.
Divestiture Impact on Sales Total sales were $386M, down $19M, reflecting an $11M volume drop and $10M impact from Avoca business sale.
Risk Factors
Credit Rating Downgrade Risk Moody's Investor Services downgraded corporate credit rating to Ba2 during the quarter, potentially affecting future borrowing costs.
Lower Volume Pressures Sales Total sales decreased $19M, driven by lower volume and unfavorable pricing, partially offset by favorable foreign currency exchange.
Trade Policy Geopolitical Uncertainty Continuing regulatory activity regarding tariffs and global trade disputes creates macroeconomic and geopolitical uncertainty risks.
Asbestos Litigation Reserves Large Total reserves for Ashland's asbestos claims stood at $246M at period end, subject to future estimation changes.
Outlook
FY2026 Adjusted EBITDA Narrowed Full year fiscal 2026 Adjusted EBITDA guidance narrowed to $400M to $420M range, reflecting temporary impacts.
Optimization Program Cost Savings Manufacturing optimization program on track, expecting $30M cost savings under the $90M program for fiscal 2026.
Core Markets Remain Resilient Personal Care and Life Sciences core end markets expected to remain resilient, supported by stable fundamentals and innovation traction.
Share Repurchase Availability High $520 million remained available for repurchase under the $1B evergreen stock repurchase program as of December 31, 2025.
Peer Comparison
Revenue (TTM)
$7.96B
$5.81B
$3.59B
Gross Margin (Latest Quarter)
56.2%
34.4%
32.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| MEOH | $4.14B | 52.6 | 3.2% | 48.2% |
| SKE | $4.03B | -45.0 | -109.2% | 9.5% |
| AVNT | $3.25B | 39.6 | 3.5% | 31.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-6.9%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 28, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data